ClinicalTrials.gg
RecruitingNCT05989659TRANSIT-CAREUpdated Feb 14, 2025

Transitioning to Home or In-center Dialysis

An observational study in Chronic Kidney Diseases, sponsored by Ciusss de L'Est de l'Île de Montréal. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Ciusss de L'Est de l'Île de Montréal · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
420
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 215 studies in Renal Insufficiency, Chronic with a site in Canada — 37 open to participants now, 61 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Canada.

Planned enrollment
24th of 41
420 · median 500
Started
2023
with 9 others
Observational
41 of 215
11 open now
Primary completion
2026-12
later than 25 of 60 live
Registered
166th of 215
by date

Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, this one is the 24th largest by planned enrollment of the 41 observational ones that give a count, is one of 10 that started in 2023, is one of 41 observational ones, reaches primary completion later than 25 of the 60 other live ones, and was the 166th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

37 of the 215 studies in Renal Insufficiency, Chronic with a site in Canada are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 215 studies in Renal Insufficiency, Chronic with a site in Canada, or all of them as a file.
02

Study summary

For people with advanced kidney disease, deciding which type of dialysis is best can be challenging. Studies have shown that quality of life is very important to patients. It is thought that the quality of life of people receiving their dialysis at home may be better than the one of people receiving dialysis in a hospital. However, how the start of dialysis changes the quality of life of people who choose home dialysis in comparison to people choosing dialysis in a hospital is still unknown.

TRANSIT-CARE is a prospective mixed methods study following adult with advanced kidney disease who progress to dialysis and receive home or hospital-based dialysis. This study aims to examine the trajectory and change in patients' quality of life and their frailty status (health, mobility and function) before start of dialysis and up to 12-month after start. Differences between people doing home dialysis and hospital-based dialysis will be assesses taking into account people's characteristics including their gender and socio-demographics characteristics. The study will include questionnaires to measure quality of life and tools to evaluate frailty. Additionally, semi-structured interviews will be done with a diverse group of patients and caregivers before and after the initiation of dialysis to better understand their experience of transitioning to dialysis.

Read the detailed description

Home dialysis has been encouraged due to its clinical benefits and lower costs, leading to increased use in recent years, even among patients with a high comorbidity burden and frailty severity. Health-related quality of life (HRQoL) is reduced in patients receiving dialysis, although patients treated with home dialysis may have relatively better patient-reported outcome measures (PROMs), than those on in-center dialysis. As the home dialysis population expands to include patients with a high frailty severity, it is unknown if these benefits are preserved. More importantly, data lacks on how the transition to home or in-center dialysis is experienced by patients and caregivers and whether changes in HRQoL and frailty impact this experience.

Objectives

  1. Determine and compare the trajectory of HRQoL, frailty and caregiver burden during the chronic kidney disease (CKD)-to-dialysis transition. (QUANTI)
  2. Examine the experience of participants during their progression from CKD to dialysis. (QUALI)
  3. Understand how HRQoL, frailty, and dialysis modality influence patients' and caregivers' experience of transition. (QUANTI+QUALI)

Design and Research Plan TRANSIT-CARE is a 5-year multicenter mixed-methods study of patients with advanced CKD and their caregivers across 12 Canadian centers, with active patient-partner engagement.

QUANTITATIVE Participant will be followed every 3-months (from estimated glomerular filtration rate [eGFR] \<12 mL/min/1.73m2) and up to 12-month after dialysis start (4-week, 3-, 6-,12-month).

Target recruitment: 420 patients / 165 caregivers. Dialysis modality will be defined as the chosen modality at baseline visit, and dichotomized as home dialysis (peritoneal or home hemodialysis) and in-center dialysis.

Changes in PROMs and frailty will be assessed using multivariable mixed linear spline regression analysis with each measure used as a continuous variable adjusted for baseline scores, chosen dialysis modality (exposure), dialysis start (time-dependent variable) and prespecified potential confounders.

QUALITATIVE Semi-structured interviews will be conducted with 30 patients and 30 caregivers (from three centers) before and after dialysis initiation.

Thematic analysis will be used to identify patient and caregiver perceptions of home and in-center dialysis, their reactions to dialysis initiation (e.g., feelings of empowerment or loss, life disruption) and perceived burden for caregivers.

Data integration Data from the qualitative and quantitative components will be integrated at time of analysis using tables and joint displays.

03

Conditions studied

  • Chronic Kidney Diseases

Keywords

  • Chronic Kidney Disease
  • Quality of Life
  • Frailty
  • Home Dialysis
  • Peritoneal Dialysis
  • Home Hemodialysis
  • Hemodialysis
  • Mixed Methods
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults followed in advanced chronic kidney disease clinics and their caregivers will be recruited from 12 academic centers across Canada

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults followed in advanced CKD clinic,
  2. estimated (eGFR) \<12 mL/min/1.73m2 103,
  3. Have chosen their dialysis modality,
  4. Understand English or French.

Exclusion criteria

Exclusion Criteria:

  1. Orientation toward conservative treatment,
  2. Planned kidney transplantation \< 6 months,
  3. Unable to provide consent due to severe cognitive or psychiatric disease,
  4. Previous treatment with dialysis > 3 months,
  5. \< 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
420 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient - Home Dialysis

    Patients transitioning to home dialysis

    Other: Exposure: Home dialysis or facility-hemodialysis

  • Patient - Facility Hemodialysis

    Patients transitioning to facility hemodialysis

    Other: Exposure: Home dialysis or facility-hemodialysis

  • Caregivers - Home dialysis

    Caregivers of patients transitioning to home dialysis

    Other: Exposure: Home dialysis or facility-hemodialysis

  • Caregivers - Facility Hemodialysis

    Caregivers of patients transitioning to facility hemodialysis

    Other: Exposure: Home dialysis or facility-hemodialysis

Interventions

  • OtherExposure: Home dialysis or facility-hemodialysis

    Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis

06

What researchers measure

Primary outcomes

  1. Change in Kidney Disease Quality of Life - 36 (KDQOL-36) - Patients

    Scale from 0-100 (0=poor , 100 = excellent )

    Time frame: From study inclusion until 12-months after dialysis start.

  2. Change in 'ZARIT' burden Interview (ZBI) - Caregivers

    Scale 0-88 (0=no/little burden, 88 = severe burden)

    Time frame: From study inclusion until 12-months after dialysis start.

Secondary outcomes

  1. Change in Fried Frailty phenotype

    5 components (slowness, weakness, weight loss, low physical activity, exhaustion) with classification as no-frail, pre-frail or frail

    Time frame: From study inclusion until 12-months after dialysis start.

  2. Change in Clinical Frailty Scale

    Scale 1 (very fit) to 9 (terminally ill)

    Time frame: From study inclusion until 12-months after dialysis start.

  3. Change in Hospital Anxiety and Depression - Patients

    14-item scale (7 anxiety, 7 depression) with score ≥8 used as cut-off for increased risk of depression and anxiety

    Time frame: From study inclusion until 12-months after dialysis start.

  4. Change in Short-form (SF)-36 - Caregivers

    Scale from 0-100 (0=poor , 100 = excellent )

    Time frame: From study inclusion until 12-months after dialysis start.

Other outcomes

  1. Semi-structured interviews with patients and caregivers

    2 interviews with patients and caregivers

    Time frame: First interview between study start and dialysis initiation / Second interview between dialysis start and up to 12-month after dialysis start.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 47 months is below that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 14, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05989659
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Collaborators
Canadian Institutes of Health Research (CIHR), The Kidney Foundation of Canada
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Jan 1, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Feb 14, 2025

Study contacts

Karine Chaussé
Contact
karine.chausse.cemtl@ssss.gouv.qc.ca
514-252-3400 ext. 3722
Annie-Claire Nadeau-Fredette, MD
principal investigator · CIUSSS de l'Est-de-l'Ile-de-Montréal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion